Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
FXR452 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00022 | 35251469 | Oxid Med Cell Longev | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | 2022 | Details |
| A00055 | 35240510 | Biochem Biophys Res Commun | Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. | 2022 | Details |
| A00096 | 35220997 | Discov Med | Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. | 2022 | Details |
| A00107 | 35217817 | Acta Pharmacol Sin | Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. | 2022 | Details |
| A00164 | 35203659 | Biomedicines | Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00257 | 35163821 | Int J Mol Sci | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. | 2022 | Details |
| A00332 | 35133032 | FASEB J | TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. | 2022 | Details |
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | 2021 | Details |
| A00472 | 35068798 | J Clin Exp Hepatol | Diagnosis and Management of Cirrhotic Cardiomyopathy. | 2021 | Details |
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00482 | 35066087 | J Hepatol | Is it time for chronopharmacology in NASH? | 2022 | Details |
| A00583 | 35040254 | Chem Biol Drug Des | SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice. | 2022 | Details |
| A00624 | 35024184 | J Adv Res | Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. | 2021 | Details |
| A00660 | 35011746 | J Clin Med | Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles. | 2021 | Details |
| A00700 | 34998040 | Eur J Med Chem | Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. | 2021 | Details |
| A00713 | 34992541 | Front Pharmacol | Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling. | 2021 | Details |
| A00726 | 34988202 | Ann Transl Med | Y-box binding protein 1 regulates liver lipid metabolism by regulating the Wnt/β-catenin signaling pathway. | 2021 | Details |
| A00731 | 34986301 | Endocrinol Metab (Seoul) | The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE-/-FXR-/- Mice. | 2021 | Details |
| A00760 | 34977519 | JHEP Rep | Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A00779 | 34970143 | Front Pharmacol | Ilexsaponin A1 Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice. | 2021 | Details |
| A00851 | 34948020 | Int J Mol Sci | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01048 | 34889100 | J Med Chem | Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. | 2021 | Details |
| A01124 | 34862975 | FASEB J | Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. | 2022 | Details |
| A01195 | 34831031 | Cells | Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01218 | 34825156 | JHEP Rep | Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A01246 | 34815180 | Trends Mol Med | Linking liver metabolic and vascular disease via bile acid signaling. | 2021 | Details |
| A01402 | 34759011 | Drug Metab Dispos | Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling. | 2021 | Details |
| A01456 | 34740705 | J Hepatol | EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. | 2021 | Details |
| A01562 | 34693236 | JHEP Rep | Non-alcoholic fatty liver disease: A patient guideline. | 2021 | Details |
| A01646 | 34669440 | Sci Transl Med | Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. | 2021 | Details |
| A01652 | 34667947 | JHEP Rep | New targets for NAFLD. | 2021 | Details |
| A01714 | 34646233 | Front Endocrinol (Lausanne) | Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders. | 2021 | Details |
| A01721 | 34639207 | Int J Mol Sci | Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. | 2021 | Details |
| A01793 | 34615727 | Gut | Novel therapeutic targets for cholestatic and fatty liver disease. | 2021 | Details |
| A02213 | 34458376 | J Immunol Res | Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway. | 2021 | Details |
| A02631 | 34302449 | Clin Pharmacol Drug Dev | Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. | 2021 | Details |
| A02648 | 34298687 | Cancers (Basel) | Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. | 2021 | Details |
| A02673 | 34289507 | Semin Liver Dis | Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. | 2021 | Details |
| A02728 | 34270928 | Cell Metab | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. | 2021 | Details |
| A02732 | 34268860 | Liver Int | NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. | 2021 | Details |
| A02796 | 34236487 | Semin Immunopathol | Role of bile acids in inflammatory liver diseases. | 2021 | Details |
| A02881 | 34206629 | Nutrients | Perinatal High-Salt Diet Induces Gut Microbiota Dysbiosis, Bile Acid Homeostasis Disbalance, and NAFLD in Weanling Mice Offspring. | 2021 | Details |
| A02995 | 34171397 | J Ethnopharmacol | Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. | 2021 | Details |
| A03212 | 34088068 | Sci Total Environ | Cadmium chloride induces non-alcoholic fatty liver disease in rats by stimulating miR-34a/SIRT1/FXR/p53 axis. | 2021 | Details |
| A03279 | 34063472 | Int J Mol Sci | The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03317 | 34047448 | Mol Nutr Food Res | Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice. | 2021 | Details |
| A03364 | 34027340 | JHEP Rep | Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | 2021 | Details |
| A03493 | 33984334 | Metabolism | A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. | 2021 | Details |
| A03701 | 33898959 | JHEP Rep | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | 2021 | Details |
| A03711 | 33895191 | Pharmacol Ther | The pathophysiological function of non-gastrointestinal farnesoid X receptor. | 2021 | Details |
| A03718 | 33894097 | Liver Int | A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis. | 2021 | Details |
| A03784 | 33865013 | Biomed Pharmacother | Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway. | 2021 | Details |
| A03802 | 33860214 | ACS Pharmacol Transl Sci | Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. | 2021 | Details |
| A03826 | 33856122 | ChemMedChem | Development and in vitro Profiling of Dual FXR/LTA4H Modulators. | 2021 | Details |
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | 2021 | Details |
| A04000 | 33794741 | Autophagy | The ménage à trois of autophagy, lipid droplets and liver disease. | 2021 | Details |
| A04029 | 33784797 | Phytother Res | Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. | 2021 | Details |
| A04106 | 33755449 | J Agric Food Chem | Gut Microbiota and Its Metabolite Deoxycholic Acid Contribute to Sucralose Consumption-Induced Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04289 | 33675775 | Biochem Pharmacol | Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model. | 2021 | Details |
| A04349 | 33652942 | Int J Mol Sci | Treatments for NAFLD: State of Art. | 2021 | Details |
| A04406 | 33630750 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. | 2021 | Details |
| A04443 | 33615207 | JHEP Rep | NASH-related increases in plasma bile acid levels depend on insulin resistance. | 2020 | Details |
| A04555 | 33581174 | J Hepatol | A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A04636 | 33555523 | J Gastrointest Surg | Gastric Bypass Increases Circulating Bile Acids and Activates Hepatic Farnesoid X Receptor (FXR) but Requires Intact Peroxisome Proliferator Activator Receptor Alpha (PPARα) Signaling to Significantly Reduce Liver Fat Content. | 2021 | Details |
| A04673 | 33545430 | Cell Mol Gastroenterol Hepatol | Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. | 2021 | Details |
| A04700 | 33535836 | Expert Rev Clin Pharmacol | An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy. | 2021 | Details |
| A04822 | 33493657 | Pharmacol Res | Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. | 2021 | Details |
| A04968 | 33435509 | Biomedicines | The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. | 2021 | Details |
| A05031 | 33401222 | Biomed Pharmacother | Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice. | 2021 | Details |
| A05237 | 33328206 | Diabetes | Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver. | 2020 | Details |
| A05346 | 33292701 | Biomark Res | Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function. | 2020 | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | 2021 | Details |
| A05479 | 33242590 | Biochim Biophys Acta Mol Basis Dis | Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy. | 2020 | Details |
| A06022 | 33036939 | Surg Obes Relat Dis | Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. | 2020 | Details |
| A06052 | 33027657 | Cell Rep | Genetic and Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and Liver Fat Content. | 2020 | Details |
| A06075 | 33015098 | Front Med (Lausanne) | Bile Acids and FXR: Novel Targets for Liver Diseases. | 2020 | Details |
| A06142 | 32991173 | J Med Chem | Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06277 | 32944984 | J Food Biochem | trans-Chalcone inhibits high-fat diet-induced disturbances in FXR/SREBP-1c/FAS and FXR/Smad-3 pathways in the kidney of rats. | 2020 | Details |
| A06319 | 32930860 | Wien Klin Wochenschr | Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. | 2020 | Details |
| A06352 | 32919135 | Bioorg Chem | Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver. | 2020 | Details |
| A06365 | 32914125 | Curr Res Food Sci | Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells. | 2020 | Details |
| A06588 | 32818571 | J Hepatol | miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder. | 2020 | Details |
| A06663 | 32790577 | Physiol Rev | Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. | 2020 | Details |
| A06671 | 32785220 | PLoS One | Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet. | 2020 | Details |
| A06750 | 32760200 | Int J Biol Sci | Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism. | 2020 | Details |
| A06866 | 32717871 | Int J Mol Sci | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. | 2020 | Details |
| A06956 | 32687365 | J Med Chem | Design and Structural Optimization of Dual FXR/PPARδ Activators. | 2020 | Details |
| A06958 | 32686578 | Expert Opin Emerg Drugs | Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. | 2020 | Details |
| A07051 | 32640454 | Pharmacology | Molecular Study on the Potential Protective Effects of Bee Venom against Fructose-Induced Nonalcoholic Steatohepatitis in Rats. | 2020 | Details |
| A07142 | 32604760 | Nutrients | Selenoneine Ameliorates Hepatocellular Injury and Hepatic Steatosis in a Mouse Model of NAFLD. | 2020 | Details |
| A07204 | 32583938 | Phytother Res | Extract of Schisandra chinensis fruit protects against metabolic dysfunction in high-fat diet induced obese mice via FXR activation. | 2020 | Details |
| A07297 | 32552182 | Expert Opin Investig Drugs | Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A07313 | 32543284 | Expert Opin Pharmacother | Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. | 2020 | Details |
| A07397 | 32514497 | JHEP Rep | Combined alcoholic and non-alcoholic steatohepatitis. | 2020 | Details |
| A07424 | 32505776 | Clin Chim Acta | Intestinal microbiota-farnesoid X receptor axis in metabolic diseases. | 2020 | Details |
| A07430 | 32502637 | Pharmacol Res | Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. | 2020 | Details |
| A07482 | 32477115 | Front Pharmacol | Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. | 2020 | Details |
| A07538 | 32451200 | Arab J Gastroenterol | The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. | 2020 | Details |
| A07622 | 32417163 | Chem Biol Interact | Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. | 2020 | Details |
| A07846 | 32336663 | Surg Obes Relat Dis | Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. | 2020 | Details |